RANK Ligand (L300) Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Transfected Only	MW (kDa): 35-45	Source/Isotype: Rabbit	UniProt ID: #O14788	Entrez-Gene Id: 8600
Product Usage Information		Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:50	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		RANK Ligand (L300) Antibody detects transfected levels of cellular RANK Ligand protein.				
Species predicted to react based on 100% sequence homology		Rat, Monkey, Bovine, P	ig			
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxyl terminus of human RANK Ligand. Antibody was purified by protein A and peptide affinity chromatography.				
Background		RANK (receptor activator of NF-кB) is a member of the tumor necrosis factor (TNF) receptor subfamily that is activated by its ligand, RANKL (TRANCE/OPGL/ODF), to promote survival of dendritic cells and differentiation of osteoclasts (1-4). Although RANK is widely expressed, its cell surface expression may be more restricted to dendritic cells and foreskin fibroblasts (1). RANK contains a 383-amino acid intracellular domain that associates with specific members of the TRAF family to NF-kB and JNK activation (1,5). RANKL/RANK signaling may also lead to survival signaling through activation of the Akt pathway and an upregulation of survival proteins, including Bcl-xL (2,6). RANK signaling has been implicated as a potential therapeutic to inhibit bone loss and arthritis (7,8).				
		(OPGL) (3), osteoclast of of the TNF family that of of immune function an expressed in activated dendritic cell survival. I	lifferentiation factor exists as both a me d bone developme T cells, as well as t Deletion of RANKL differentiation, loss	tion-induced cytokine (1 or (ODF) (4), and TNFSF1 embrane-bound and soli ent and homeostasis (7, he thymus, lymph node in mice leads to severe s of lymph node develor	1, is a type II transr uble form. It is an e 10,11). RANKL is pre , and bone marrow osteoporosis with a	nembrane protein ssential regulator edominately and promotes loss of osteoclasts,
Background References		1. Anderson, D.M. et al. (1997) <i>Nature</i> 390, 175-9. 2. Wong, B.R. et al. (1998) <i>Cell</i> 93, 165-76. 3. Lacey, D.L. et al. (1998) <i>Proc. Natl. Acad. Sci. USA</i> 95, 3597-602. 5. Darnay, B.G. et al. (1998) <i>J. Biol. Chem.</i> 273, 20551-5. 6. Wong, B.R. et al. (1999) <i>Mol. Cell</i> 4, 1041-9. 7. Walsh, M.C. and Choi, Y. <i>Cytokine Growth Factor Rev.</i> 14, 251-63. 8. Nakashima, T. et al. (2003) <i>Curr. Opin. Rheumatol.</i> 15, 280-7. 9. Wong, B.R. et al. (1997) <i>J Biol Chem</i> 272, 25190-4. 10. Hofbauer, L.C. (1999) <i>Eur J Endocrinol</i> 141, 195-210. 11. Theill, L.E. et al. (2002) <i>Annu Rev Immunol</i> 20, 795-823. 12. Mizuno, A. et al. (1998) <i>Biochem Biophys Res Commun</i> 247, 610-5. 13. Kong, Y.Y. et al. (1999) <i>Nature</i> 397, 315-23. 14. Fata, J.E. et al. (2000) <i>Cell</i> 103, 41-50.				

Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X

TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting IP: Immunoprecipitation

Cross-Reactivity Key H: Human

Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for

more information.

Limited UsesExcept as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's

terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no

force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.